Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|3|242-249

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.3, 2015-03, pp. : 242-249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment‐free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 2, 2015-01 ,pp. : 305-308

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

By Saleh Mansoor N.   Haislip Sally   Sharpe Joyce   Hess Tamara   Gilmore James   Jackson James   Sail Kavita R.   Ericson Solveig G.   Chen Lei  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 529-536

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite

Molecular monitoring of chronic myeloid leukemia: a personalized approach to optimizing treatment response

By Nichols Linda   Pippins Julie   Castle Lon   Cassler Mary   Fuller Courtney  

Personalized Medicine, Vol. 9, Iss. 7, 2012-09 ,pp. : 727-737

Future Medicine

Access to resources Recommend Favorite